A recent survey of biotechnology-derived medicines and vaccines under development showed that the largest fraction of these were monoclonal antibodies for the detection and/or treatment of cancer. This article describes the role and function of the nuclear pharmacist in the initiation, development, and conduct of a prototype clinical trial in which a radiolabeledmonoclonal antibody (MAb) is used as a diagnostic imaging agent to detect the site of a tumor in a patient who is being managed in a hospital outpatient setting. Examples are used to illustrate selected pharmaceutical care issues in this investigational environment.
Get full access to this article
View all access options for this article.
References
1.
MossinghoffGJ: Biotechnology medicine in development: Results of 1991 survey report. Washington, DC, Pharmaceutical Manufacturers Association, 1992.
KohlerGMilsteinC: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature256:495–497, 1975.
4.
Amgen: Biotechnology: Overview and outlook for the 1990's. Presented at the 1992 Annual Meeting of the American Pharmaceutical Association, San Diego, CA, 1992.
5.
RoittIMaleBrosloff J (eds): Immunology. St. Louis, MO, CV Mosby, 1985.
NabiHA: Clinical radioimmunoscintigraphy. Administrative Radiology, May 1992.
8.
NabiHADoerrRJ: Clinical applications of In-111 labeled monoclonal antibody imaging in colorectal cancer patients. Semin Nucl Med23:99–113, 1993.
9.
LevineG: A dick and jane primer on radiolabeled monoclonal antibodies for imaging. Pittsburgh, PA, Pittsburgh Chapter-Society of Nuclear Medicine Technologist Newsletter, September 1992.
10.
HalpernSE: An overview of radioimmunoimaging, in MaguireRTVan NostrandD (eds): Diagnosis of Colorectal and Ovarian Carcinoma. New York, NY, Marcel Dekker, 1992, pp 1–22.
11.
McKearnT: Future directions in radioimmunodetection, in MaguireRTVan NostrandD (eds): Diagnosis of Colorectal and Ovarian Carcinoma. New York, NY, Marcel Dekker, 1992, pp 211–229.
12.
GoldPFreedmanS: Specific carcinoembryonic antigens of the human digestive system. J Exp Med122:467–481, 1965.
13.
TronVWrightJLChungA: Carcinoembryonic antigen and milk-fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung. Arch Pathol Lab Med111:291–293, 1987.
14.
GoldenbergDM: Radioimmunodetection of cancer: A retrospective view. New Perspect Cancer Diagn Manag1:4–10, 1993.
15.
GoldenbergDMBlumenthalRDSharkeyRM: Biological and clinical perspectives of cancer imaging and therapy with radiolabeled antibodies. Semin Can Biol1:217–225, 1990.
16.
GoldenbergDMDeLandFKimE: Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by photoscanning. N Engl J Med298:1384–1388, 1978.
17.
GoldenbergDMGoldenbergHSharkeyRM: Imaging of colorectal carcinoma with radiolabeled antibodies. Semin Nucl Med19:262–281, 1989.
18.
BallouBLevineGHakalaT: Tumor localization detected with radioactively labeled monoclonal antibody and external scintigraphy. Science206:844–847, 1979.
19.
LevineGBallouBReilandJ: Localization of I-131 labeled tumor specific monoclonal antibody in the tumor bearing balb/c mouse. J Nucl Med21:570–573, 1980.
20.
HinkleGH: The development of radiolabeled antibodies for nuclear medicine imaging of cancer. New Perspect Cancer Diagn Manag1:14–23, 1993.
21.
LarsonSM: Clinical radioimmunodetection, 197801988: Overview and suggestions for standardization of clinical trials. Cancer Res50:892–898, 1990 (Suppl).
22.
LevineGAbelN: Considerations in the assembly and submission of the physician-sponsored investigational new drug application, in HladikWBSahaGStudyKT (eds): Essentials of Nuclear Medicine Science. Baltimore, MD, Williams & Wilkins, 1987, pp 357–386.
23.
DeJagerRNabiHASerafiniA: Current status of cancer immunodetection with radiolabeled human monoclonal antibodies. Semin Nucl Med23:165–179, 1993.
24.
EdingtonHDWatsonCGLevineG: Radioimmunoimaging of metastatic medullary carcinoma of the thyroid using an Indium-111 labeled monoclonal antibody to CEA. Surgery104:1004–1010, 1988.
25.
CorstensFHMOyenWJGBeckerWS: Radioimmunoconjugates in the detection of infection and inflammation. Semin Nucl Med23:148–164, 1993.
26.
HoffkenHJosephKBeerR: In vivo labelling of thrombocyte with monoclonal antibody Tc99m BW4 for imaging phlebothrombosis. Prog Clin Biol Res355:343–349, 1990.
KroissAWeissACKolblC: Immunoscintigraphy (is) with I-123 and Tc99m labeled granulocyte antibody (ab) in patients with inflammatory bowel diseases. Proc Clin Biol Res355:319–325, 1990.
29.
ManspeakerPWeismanHFSchaibleTF: Cardiovascular applications: Current status of immunoscintigraphy in the detection of myocardial necrosis using antimyosis (R11DIO) and deep venous thrombosis using antifibrin (T2GIs). Semin Nucl Med23:133–147, 1993.
30.
McKearnT: Future directions in radioimmunodetection, in MaguireRTVan NostrandD (eds): Diagnosis of Colorectal and Ovarian Carcinoma. New York, NY, Marcel Dekker, 1992, pp 211–229.
31.
MiketicLMChambersPLemberskyBC: Cutaneous T-cell lymphoma: Value of CT in staging and determining prognosis. AJR160:1129–1132, 1993.
32.
Omnibus Budget Reconciliation Act of 1990: Washington, DC, US Government Printing Office, 1990, pp 152–171.
33.
ReutzelTJWilsonLAMickelM: Inner city pharmacies: can they meet the OBRA '90 mandates?Am Pharm NS33:44–51, 1993.
34.
WebsterWBLavenDL: Pharmacokinetic and biologic distribution studies of Indium-111 labeled monoclonal antibodies. New Perspect Cancer Diagn Manag1:42–47, 1993.
